Table 1.
Eight references under the PICOS principle
| P (population) | I (intervention) | C (comparison) | O (outcome) | S (study design) | |
|---|---|---|---|---|---|
| Fugun Wei 2021 | Advanced aHCC | Lenvatinib plus Camrelizumab | Lenvatinib | Effectiveness and Safety | Cohort |
| Kang Chen 2022 | Unresectable aHCC | Lenvatinib plus ICIs | Lenvatinib | Effectiveness and Safety | Cohort |
| Lei Zhao 2022 | Unresectable aHCC | Lenvatinib plus Sintilimab | Lenvatinib | Effectiveness and Safety | Cohort |
| Qi Li 2022 | Unresectable aHCC | Lenvatinib plus Camrelizumab | Lenvatinib | Effectiveness and Safety | Cohort |
| R.S. Finn 2022 | Advanced aHCC | Lenvatinib plus Pembrolizumab | Lenvatinib | Effectiveness and Safety | RCT |
| Wen-Chi Wu 2022 | Advanced aHCC | Lenvatinib plus Nivolumab | Lenvatinib | Effectiveness and Safety | Cohort |
| Xiaohui Wang 2023 | Advanced aHCC | Lenvatinib plus ICIs | Lenvatinib | Effectiveness | Cohort |
| Yu-Xian Teng 2022 | Advanced aHCC | Lenvatinib plus ICIs | Lenvatinib | Effectiveness | Cohort |